Faculty profile

Michael Sebag

ResearcherMedicineMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Michael Sebag

Researcher

Medicine

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
36 publications in the last five years, latest in 2026.
Principal investigator on 1 research grant (1 CIHR), most recently in 2012.
Supervisor on 2 trainee awards (2 CIHR), most recently in 2010.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

130

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Bisphosphonates Bone Disease Multiple Myeloma Novel Therapies Osteoblasts Osteoclasts

Latest papers

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy
Transplantation and Cellular Therapy · 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report
Blood Neoplasia · 2026
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Clinical Lymphoma, Myeloma and Leukemia · 2026

All 56 publications

Latest funding

Geranylgeranylation Inhibitors as Novel Therapeutics for the Treatment of TP53 Wild Type and Mutated Acute Myeloid Leukemia (AML)
CIHR · 2026 · Co-investigator
$986,850
Molecular Tools that Block Maturation of the Nuclear Lamin A, Leading to Decrease in Proliferation and Metastasis of Pancreatic Ductal Adenocarcinoma and Colorectal Cancer
CIHR · 2022 · Co-investigator
$1,071,000
Viral diversity and immune escape variants in vulnerable individuals post-vaccination.
CIHR · 2021 · Co-investigator

All 12 grants and awards

56 publications.

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Buchan CA, Agbayani G, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Transplantation and Cellular Therapy20263 citations

DOI: 10.1016/j.jtct.2025.10.037

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Louzada ML, Reece D, Venner CP, White D, Su J, Chu MP, Zepeda VHJ, Mccurdy A, Song K, Mian H

Blood Neoplasia2026

DOI: 10.1016/j.bneo.2026.100215

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Varghese J, Venner CP, Louzada M, Reece D, White D, Sharma S, Su J, Chu MP, Jimenez-Zepeda VH, McCurdy A

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.019

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Kaedbey R, Venner CP, Reece D, Hay K, Gul E, Su J, McCurdy A, Chu MP, Jimenez-Zepeda VH, Song K

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.026

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM

Blood advances2026

DOI: 10.1182/bloodadvances.2025018117

Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada

Mian HS, Visram A, Shih SC-M, Trudel S, Hay AE, LeBlanc R, Sebag M, Kaedbey R, Stakiw J, Sandhu I

Clinical Lymphoma, Myeloma and Leukemia20253 citations

DOI: 10.1016/j.clml.2025.01.010

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

McCurdy A, Gul E, Reece D, Chu MP, Jimenez-Zepeda VH, Louzada M, Song K, Mian H, Sebag M, White D

Clinical Lymphoma, Myeloma and Leukemia20252 citations

DOI: 10.1016/j.clml.2025.02.011

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

Vijenthira A, Bhella S, Hueniken K, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Balitsky A

British Journal of Haematology2025

DOI: 10.1111/bjh.70054

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.

Pelland AA, Dumas M, Lemieux-Blanchard É, LeBlanc R, Côté J, Boudreault JS, Duquette D, Kaedbey R, Lalancette M, Larose F, Nikonova A, Pavic M, Shamy A, Roy J, Sebag M, Trudel S, Claveau JS

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32040238 PMID: 40277794

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.

Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV, RedirecTT-1 Investigators and Study Group

The New England journal of medicine2025

DOI: 10.1056/nejmoa2406536 PMID: 39778168

Something wrong or missing on this profile? Suggest a correction

Michael Sebag

Research

Latest papers

Latest funding

Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.

Frequent collaborators

Donna Reece

Arleigh McCurdy

Martha Louzada

Hira Mian

Alissa Visram

Curtis Cooper

Amaris Karin Balitsky

Suzanne Trudel

Marc-André Langlois

Christopher Bredeson

David Allan

Natasha Kekre

Jerry Pelletier

Alexandre Orthwein

Ivan Topisirovic

Christopher Venner

Shelly Bolotin

Julie St-Pierre

Ivan Topisirovic

Laura Hulea

Matthew Cheung

Deepali Kumar

James Brooks